Linda West - Jun 15, 2021 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Role: Director
Signature: /s/ Christopher Degnan, Attorney-in-Fact for Linda West
Stock symbol: GRTX
Transactions as of: Jun 15, 2021
Transactions value $: $91,300
Form type: 4
Date filed: 6/17/2021, 06:41 PM
Previous filing: Jun 4, 2021
Next filing: Jul 6, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GRTX	Common Stock	Purchase	$91.3K	+10K	+33.33%	$9.13^*	40K	Jun 15, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GRTX	Stock Option (Right to Buy)	Award	$0	+9.89K		$0.00	9.89K	Jun 16, 2021	Common Stock	9.89K	$8.90	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $9.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $9.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.